329 related articles for article (PubMed ID: 16160731)
1. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
[TBL] [Abstract][Full Text] [Related]
2. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis.
Smith EJ; McEvoy A; Little DG; Baldock PA; Eisman JA; Gardiner EM
J Bone Miner Res; 2004 Oct; 19(10):1698-705. PubMed ID: 15355565
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis.
Little DG; Smith NC; Williams PR; Briody JN; Bilston LE; Smith EJ; Gardiner EM; Cowell CT
J Bone Miner Res; 2003 Jul; 18(7):1300-7. PubMed ID: 12854841
[TBL] [Abstract][Full Text] [Related]
4. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
[TBL] [Abstract][Full Text] [Related]
5. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model.
Yildiz A; Esen E; Kürkçü M; Damlar I; Dağlioğlu K; Akova T
J Oral Maxillofac Surg; 2010 Mar; 68(3):515-23. PubMed ID: 20171470
[TBL] [Abstract][Full Text] [Related]
6. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.
Amanat N; McDonald M; Godfrey C; Bilston L; Little D
J Bone Miner Res; 2007 Jun; 22(6):867-76. PubMed ID: 17371160
[TBL] [Abstract][Full Text] [Related]
7. Lack of an effect of sodium zeolite A on rat tibia histomorphometry.
Firling CE; Evans GL; Wakley GK; Sibonga J; Turner RT
J Bone Miner Res; 1996 Feb; 11(2):254-63. PubMed ID: 8822350
[TBL] [Abstract][Full Text] [Related]
8. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
Malmgren B; Aström E; Söderhäll S
J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
[TBL] [Abstract][Full Text] [Related]
9. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
[TBL] [Abstract][Full Text] [Related]
10. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis.
Arrington SA; Damron TA; Mann KA; Allen MJ
J Surg Oncol; 2008 Mar; 97(3):284-90. PubMed ID: 18161868
[TBL] [Abstract][Full Text] [Related]
11. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
[TBL] [Abstract][Full Text] [Related]
12. No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site.
Biver E; Vieillard MH; Cortet B; Salleron J; Falgayrac G; Penel G
Bone; 2010 Mar; 46(3):643-8. PubMed ID: 19895916
[TBL] [Abstract][Full Text] [Related]
13. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic acid-treated rats.
Basi DL; Hughes PJ; Thumbigere-Math V; Sabino M; Mariash A; Lunos SA; Jensen E; Gopalakrishnan R
J Oral Maxillofac Surg; 2011 Nov; 69(11):2698-707. PubMed ID: 21752506
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.
Little DG; McDonald M; Bransford R; Godfrey CB; Amanat N
J Bone Miner Res; 2005 Nov; 20(11):2044-52. PubMed ID: 16234978
[TBL] [Abstract][Full Text] [Related]
16. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
Gökşen D; Coker M; Darcan S; Köse T; Kara S
Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
[TBL] [Abstract][Full Text] [Related]
17. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
[TBL] [Abstract][Full Text] [Related]
18. Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits.
Pampu AA; Dolanmaz D; Tüz HH; Avunduk MC; Kişnişci RS
J Oral Maxillofac Surg; 2008 May; 66(5):905-10. PubMed ID: 18423279
[TBL] [Abstract][Full Text] [Related]
19. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
20. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
Kamoun-Goldrat A; Ginisty D; Le Merrer M
Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
